Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC

Author(s):

Panelists discuss the role of immunotherapy in the treatment landscape for BRAF-positive NSCLC, considering factors influencing the choice between immunotherapy and targeted therapy, emerging therapies, ongoing clinical trials, and approaches to dosing, sequencing, and toxicity management for both ALK and BRAF inhibitors.

Dr Bestvina: What are your thoughts on incorporating immunotherapy into the treatment landscape for BRAF-positive NSCLC? (Wang H, et al. 2023. Transl Lung Cancer Res)
What factors do you consider when deciding between immunotherapy (IO) and targeted therapy as first-line treatment for patients with BRAF V600E-mutated NSCLC)?
What emerging therapies or combinations for BRAF-positive NSCLC are you most excited about?
Please highlight any ongoing clinical trials that might change your approach to treating patients with BRAF-positive NSCLC.
What is your approach to dosing and sequencing of ALK and BRAF inhibitors in NSCLC?
How do you adapt treatment approaches for elderly patients or those with poor PFS?
What is your approach to managing patients with rare ALK fusion variants?
Please share your approach to managing toxicities while maintaining efficacy with ALK and BRAF inhibitors. (Bauer T, et al. 2024. WCLC MA06.08)
How do you approach dose adjustments in the event of adverse events?
What are the key considerations for maintaining dose intensity while managing toxicities in long-term treatment?